Tuesday March 26, 2019

By 2030, Over 98 mn Indians Will Have Diabetes, Lancet Study Revealed

Insulin is essential for all people with Type-1 diabetes and some people with Type-2 diabetes to reduce the risk of complications such as blindness, amputation, kidney failure, and stroke

0
//
Diabetes
Representational image. Pixabay

While Type-2 diabetes is expected to rise by more than a fifth, from 406 million in 2018 to 511 million in 2030 globally, India along with China and the US will share over half of these high blood sugar cases, say researchers led by one of an Indian-origin, while asserting the need to improve access for the life saving insulin.

The study, published in The Lancet Diabetes and Endocrinology journal, showed that China (130 million) followed by India (98 million), and the US (32 million) will constitute over half of Type-2 diabetics by 2030.

As a result, the amount of insulin needed to effectively treat Type-2 diabetes will rise by more than 20 per cent worldwide over the next 12 years.

Compared to current levels of insulin access, if universal global access was achieved (with a treatment target of HbA1c — measure of blood glucose) seven per cent or lower, the number of people with Type-2 diabetes worldwide using insulin in 2030 would double from around 38 million (7.4 per cent of all people with Type-2 diabetes) to 79 million (15.5 per cent), the researchers said.

“Despite the UN’s commitment to treat non-communicable diseases and ensure universal access to drugs for diabetes, across much of the world insulin is scarce and unnecessarily difficult for patients to access,” said lead author Sanjay Basu from Stanford University, US.

Diabetes
Representational image. Pixabay

“The number of adults with Type-2 diabetes is expected to rise over the next 12 years due to ageing, urbanisation, and associated changes in diet and physical activity.

“Unless governments begin initiatives to make insulin available and affordable, then its use is always going to be far from optimal,” Basu said.

For the study, the team used data from the International Diabetes Federation and 14 cohort studies and estimated the burden of Type-2 diabetes in 221 countries and territories between 2018 and 2030.

Also Read- HTC Not Quitting Smartphone Business: Report

Insulin is essential for all people with Type-1 diabetes and some people with Type-2 diabetes to reduce the risk of complications such as blindness, amputation, kidney failure, and stroke.

As global rates of Type-2 diabetes soar and people live longer (which will increase insulin requirements), a comprehensive picture of global insulin need is required because insulin treatment is costly and the international insulin market is presently dominated by only three major manufacturers, the researchers noted. (IANS)

Next Story

Cardiovascular Events Cause 58% Deaths Among Diabetics

The medicine likewise helps lower the amount of sodium in the body and reduce triglyceride levels and blood pressure

0
Diabetes
Representational image. Pixabay

Fifty-eight percent of deaths among people with type 2 diabetes are due to cardiovascular events, a leading Mexican expert has said.

“Patients who live with this disease have a greater risk of premature death or disability derived from cardiovascular events,” Hector Sanchez Mijangos, President of the Mexican Diabetes Federation, told Efe news.

The specialist said that the high glucose levels associated with diabetes damage blood vessels, resulting in problems with blood pressure and vision, joint pain and other maladies.

Data from the World Health Organization indicate that more 442 million people suffer from type 2 diabetes.

Mexico’s Health Secretariat has found that while roughly 13 million inhabitants of the Aztec nation are living with diabetes, only half of those afflicted know they have the disease.

In 2015 alone, according to Mijangos, there were more than 98,000 premature deaths in Mexico related to diabetes and the average age of those who died was 66.7 years old.

Diabetes
Representational image. Pixabay

“This is regrettable, because these people could have lived roughly another 15 years,” he said.

According to the 2012 National Health and Nutrition Survey, only 25 percent of Mexicans suffering with diabetes are managing their condition adequately.

That figure illustrates “why our greatest challenge continues to be access and adherence to treatment”, Mijangos said.

Also Read- Researchers Discover Balance of Two Enzymes That May Help Treat Pancreatic Cancer

To improve treatment options, Mexican health authorities in January issued an approval for the use of canagliflozin, a drug that helps reduce the amount of blood glucose reabsorbed by the kidneys, which in turns causes more glucose to be eliminated through urination.

“With this medicine, a person can lose 100 milligrams of glucose per day as well as about 400 kilocalories (4,000 calories) a day, which also helps with weight loss,” Mijangos said.

The medicine likewise helps lower the amount of sodium in the body and reduce triglyceride levels and blood pressure.

A scientific trial involving more than 10,000 patients worldwide showed that when combined with conventional treatment, canagliflozin can reduce the incidence of cardiovascular events by up to 18 percent. (IANS)